Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) can contribute to weight gain in specific circumstances, even though its licensed purpose is weight loss. The situations where gaining weight on semaglutide becomes a real risk are well-understood clinically, and knowing about them changes the decisions worth making. These are prescription-only medicines; a prescriber assesses whether treatment is appropriate for you before anything is dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
For most people, semaglutide produces meaningful, progressive weight loss over months. The STEP 1 trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, which gives a reliable sense of what the medicine does under controlled conditions.
So does semaglutide make you gain weight while you're taking it? Rarely, and usually temporarily. In the early weeks, some people notice the number on the scale creeping up slightly before it falls. This is often water retention or a shift in digestive contents rather than fat gain. The slower gastric emptying that semaglutide causes means food sits in the stomach longer, which can register on a scale without representing actual weight gain. If you want to understand whether Wegovy can cause weight gain during treatment, including the specific circumstances where it sometimes does, that page walks through each scenario in detail.
A more meaningful concern is lean muscle. If appetite suppression is strong and protein intake drops sharply without deliberate effort to maintain it, the body can lose muscle alongside fat. Muscle is metabolically active tissue. Losing too much of it while weight falls can make future weight maintenance harder. This is why prescribers and dietitians consistently flag protein adequacy and some form of resistance activity as practical priorities alongside treatment, not optional extras.
If the scale is genuinely moving up during active treatment and it persists beyond a couple of weeks, that is worth raising with your prescriber rather than adjusting your dose on your own. There are specific medical reasons weight can rise despite treatment, and a clinician needs to be involved in working through them. You can read more about the specific patterns involved at our page on what causes weight gain on Wegovy.
The most consistent answer to "can Wegovy make you gain weight" is yes, after stopping. The appetite-suppressing effect of semaglutide depends on the medicine being present and active in your system. When you stop injecting, that effect fades, typically over several weeks, and hunger levels tend to return toward where they were before treatment started.
The STEP 4 withdrawal trial tracked participants who had already lost weight on semaglutide and then either continued or switched to placebo. Those who stopped regained, on average, about two-thirds of the weight they had lost within twelve months. The NHS medicines page for semaglutide also notes that weight loss is typically not maintained after stopping.
This is not a failure of willpower. The biological signals that regulate hunger and energy balance are genuinely altered by the medicine while it is active, and the brain's set-point for body weight does not simply reset to a lower number when treatment stops. Understanding this before starting treatment helps people plan more realistically, particularly around how long they intend to use it and what lifestyle structures will need to be in place when they do stop. Our page on what happens when you stop Wegovy covers the evidence on this in more detail.
It is also worth knowing that cost is a real-world factor in this decision for many people. Looking honestly at what Wegovy costs privately over time can help frame a realistic conversation with your prescriber about duration and planning.
The pattern here is that weight gain connected to semaglutide treatment is rarely random. It follows predictable decisions: stopping abruptly, running very low on calories without protecting protein, or assuming the medicine will carry all the weight-management work indefinitely without any accompanying lifestyle structure.
None of these are decisions to make alone. The dose schedule, the duration of treatment, how to titrate down safely if you do stop, what to prioritise eating during treatment, all of this sits properly within a prescriber-led conversation. For anyone considering whether semaglutide is suitable for them in the first place, our overview of Eli Lilly semaglutide covers the background on how this class of medicine works and what to expect from it before you commit to a clinical assessment.
At nume, a real prescriber reviews every consultation the same day it arrives, not software. If you're weighing up whether treatment is right for your situation, you can explore the full picture on our Wegovy treatment page or look at how semaglutide compares to other approaches on the weight loss treatments overview. When you're ready to take the next step, speak to our prescribers through a free consultation, your assessment is reviewed the same day, and if treatment is clinically appropriate, your medication is dispatched the same afternoon and arrives the next working day in a plain, unbranded box via DPD.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.